Search research articles
Contact Us
Filters
Showing results (11-20 of 16) with videos related to
Page
of 2
Sort By:
You have reached the last page of results.
This site can display upto 16 results.
Pharmacological Research
|
May 8, 2021
Plumbagin suppresses non-small cell lung cancer progression through downregulating ARF1 and by elevating CD8<sup>+</sup> T cells
Ze-Bo Jiang, Cong Xu, Wenjun Wang, et al.
Cancer Letters
|
May 30, 2021
Luteolin and its derivative apigenin suppress the inducible PD-L1 expression to improve anti-tumor immunity in KRAS-mutant lung cancer
Ze-Bo Jiang, Wen-Jun Wang, Cong Xu, et al.
International Journal of Cancer
|
February 21, 2019
Identification of a new inhibitor of KRAS-PDEδ interaction targeting KRAS mutant nonsmall cell lung cancer
Elaine Lai-Han Leung, Lian Xiang Luo, Ying Li, et al.
Pharmacological Research
|
July 15, 2023
CERS4 predicts positive anti-PD-1 response and promotes immunomodulation through Rhob-mediated suppression of CD8<sup>+</sup>Tim3<sup>+</sup> exhausted T cells in non-small cell lung cancer
Jian Wang, Run-Ze Li, Wen-Jun Wang, et al.
Pharmacological Research
|
March 22, 2023
β-Elemene enhances erlotinib sensitivity through induction of ferroptosis by upregulating lncRNA H19 in EGFR-mutant non-small cell lung cancer
Cong Xu, Ze-Bo Jiang, Le Shao, et al.
Pharmacological Research
|
August 22, 2021
Metabolomics and integrated network pharmacology analysis reveal Tricin as the active anti-cancer component of Weijing decoction by suppression of PRKCA and sphingolipid signaling
Jia-Xin Li, Run-Ze Li, Ao Sun, et al.
Page
of 2
Search research articles
Search
Showing results (11-20 of 16) with videos related to
Sort By:
Page
of 2
You have reached the last page of results.
This site can display upto 16 results.
Pharmacological Research
|
May 8, 2021
Plumbagin suppresses non-small cell lung cancer progression through downregulating ARF1 and by elevating CD8<sup>+</sup> T cells
Ze-Bo Jiang, Cong Xu, Wenjun Wang, et al.
Cancer Letters
|
May 30, 2021
Luteolin and its derivative apigenin suppress the inducible PD-L1 expression to improve anti-tumor immunity in KRAS-mutant lung cancer
Ze-Bo Jiang, Wen-Jun Wang, Cong Xu, et al.
International Journal of Cancer
|
February 21, 2019
Identification of a new inhibitor of KRAS-PDEδ interaction targeting KRAS mutant nonsmall cell lung cancer
Elaine Lai-Han Leung, Lian Xiang Luo, Ying Li, et al.
Pharmacological Research
|
July 15, 2023
CERS4 predicts positive anti-PD-1 response and promotes immunomodulation through Rhob-mediated suppression of CD8<sup>+</sup>Tim3<sup>+</sup> exhausted T cells in non-small cell lung cancer
Jian Wang, Run-Ze Li, Wen-Jun Wang, et al.
Pharmacological Research
|
March 22, 2023
β-Elemene enhances erlotinib sensitivity through induction of ferroptosis by upregulating lncRNA H19 in EGFR-mutant non-small cell lung cancer
Cong Xu, Ze-Bo Jiang, Le Shao, et al.
Pharmacological Research
|
August 22, 2021
Metabolomics and integrated network pharmacology analysis reveal Tricin as the active anti-cancer component of Weijing decoction by suppression of PRKCA and sphingolipid signaling
Jia-Xin Li, Run-Ze Li, Ao Sun, et al.
Page
of 2